Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea.

By C. Mueller, A. Scholer, K. Laule-Kilian, B. Martina, C. Schindler, P. Buser, M. Pfisterer, A. Perruchoud. New England Journal of Medicine, 2004

1,007 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. (2009, neutral): “Current smoking 173 (24) 35 (28) 138 (23) 0.”
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. (2017, background): “chronic ambulatory HF (15-21) or in the setting of acute care with decompensated HF (22-30), especiall y”
State of the art: Using natriuretic peptide levels in clinical practice (2008, methodology): “NP levels improve the accuracy of physician decision-making; errors decline, and a marked reduction in the rate of clinical indecision would have occurred if NP levels were considered as part of the initial evaluation [14,16,22,23].”
RNA silencing: Methods and protocols (2006, background): “Several studies have indicated that the use of natriuretic peptides at the emergency department results in a better and quicker diagnosis, leading to reduced length of hospital stay and hospital costs [3, 4].”
Narrative Review (2012, background): “The measurement of B-type natriuretic peptides on presentation to the ED has been demonstrated to improve the management and reduce the hospital cost of patients with suspected HF.(26,27) Independent of their diagnostic value, several large-scale studies have shown that BNP and NT-proBNP provide str”